8 WAYS CANNABIS BENEFITS MULTIPLE SCLEROSIS PATIENTS What Is Multiple Sclerosis? Multiple Sclerosis is an autoimmune disease that attacks the protective covering of central nerves, causing inflammation resulting in a variety of symptoms. Depending on the patient and the level of their condition, symptoms can include: Extreme fatigue Lack of coordination Weakness Tingling Impaired sensation Vision problems Bladder incontinence Cognitive impairment Mood Swings Despite Canada having one of the highest rates of MS in the world, with approximately 1 in every 385 individuals battling this condition, there is still much research to be done and no cure in sight yet. However, that does not mean that patients of this disease need to suffer alone. MULTIPLE SCLEROSIS AND CANNABIS Fortunately, cannabis has been proven to assist with many of the symptoms presented by this disease and can help provide much needed comfort and emotional well-being. Cannabis Manages Pain One of the most common overall uses for cannabis is for pain relief, specifically relief from chronic pain or pain due to inflammation (arthritis). When it comes to Multiple Sclerosis, inflammation is one of the main causes of the condition and can result in pain throughout the body. In fact, 55% of M.S. patients have “clinically significant pain� while 48% are troubled by chronic pain. Cannabis has potent anti-inflammatory properties due to the bodies interactions with cannabinoids (THC and CBD) as well as the medical benefits presented by terpenes. The best strains for managing pain include those that are Indica-dominant as these present more physical properties. Some great choices for potent pain relief include: Granddaddy Purple, Purple Kush, MK Ultra and Death Bubba. Cannabis Reduces Spasticity Muscle stiffness and spasticity are common symptoms of Multiple Sclerosis. This is caused by the damage or destruction that inflammation brings to the myelin sheaths, which are responsible for protecting the nerves, and the damage can result in uncontrollable spasms. A 2007 study found decreased spasticity of over 30% in 40 percent of the patients.